SEARCH

SEARCH BY CITATION

References

  • 1
    Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F et al. International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483491.
  • 2
    Anonymous (writing group: Beasley R, Keil U, Von Mutius E, Pearce N, on behalf of ISAAC Steering Committee). Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998;351:12251232.
  • 3
    Anonymous (writing group: Asher MI, Anderson HR, Stewart AW, Crane J, Ait-Khaled N, Anabwani G et al). Worldwide variations in the prevalence of asthma symptoms: International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998;12:315335.
  • 4
    Strachan D, Sibbald B, Weiland S, Aït-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC). Paediatr Allergy Immunol 1997;8:161176.
  • 5
    Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. JAllergy Clin Immunol 1999;103:125138.
  • 6
    Stewart AW, Mitchell EA, Pearce N, Strachan DP, Weiland SK, on behalf of the ISAAC Steering Committee. The relationship of per capita gross national product to the prevalence of symptoms of asthma and other atopic diseases in children (ISAAC). Int J Epidemiol 2001;30:173179.
  • 7
    Ellwood P, Asher MI, Björkstén B, Burr M, Pearce N, Robertson CF et al. Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. Eur Respir J 2001;17:436443.
  • 8
    Weiland SK, Hüsing A, Strachan DP, Rzehak P, Pearce N, and the ISAAC Phase One Study Group. Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children. Occup Environ Med 2004; 61:609615.
  • 9
    Von Mutius E, Pearce N, Beasley R, Cheng S, Von Ehrenstein O, Björkstén B et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis and eczema. Thorax 2000; 55:449453.
  • 10
    Burr ML, Emberlin JC, Treu R, Cheng S, Pearce NE, and the ISAAC Phase One Study Group. Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC). Clin Exp Allergy 2003;33:16751680.
  • 11
    Weiland SK, Björkstén B, Brunekreef B, Cookson WO, Von Mutius E, Strachan DP et al. Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): rationale and methods. Eur Respir J 2004;24:406412.
  • 12
    Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW, and the ISAAC Steering Committee. The International Study of Asthma and Allergies in childhood (ISAAC): Phase Three rationale and methods. Int J Tuberc Lung Dis 2005;9:1016.
  • 13
    Asher MI, Montefort S, Björkstén B, Lai CK, Strachan D, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733743.
  • 14
    Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D, the ISAAC Phase Three Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19:110124.
  • 15
    World Bank. World Bank GNI per capita data for 2001. http://ddp-ext.worldbank.org/ext/DDPQQ/member.do?method=getmembers, accessed 8 April 2008.
  • 16
    Weinmayr G, Forastiere F, Weiland SK, Rzehak P, Abramidze T, Annesi-Maesano I et al. International variation in prevalence of rhinitis and its relationship with sensitisation to perennial and seasonal allergens. Eur Respir J 2008;32:12501261.
  • 17
    Aït-Khaled N, Auregan G, Bencharif N, Camara LM, Dagli E, Djankine K et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000;4:268271.
  • 18
    Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001;79:971979.
  • 19
    Bousquet J, Ndiaye M, Aït-Khaled N, Auregan G, Annesi-Maesano I, Vignola AM. Management of chronic respiratory and allergic diseases in developing countries. Focus on sub-Saharan Africa. Allergy 2003;58:265283.
  • 20
    Gelders S, Ewen M, Noguchi N, Laig R. Price, availability and affordability, an international comparison of chronic diseases medicines. Report 169 pages, WHO office for the Eastern Mediterranean Region, WHO-EM/EDB/06/E, Cairo, 2006.
  • 21
    Ait-Khaled N, Enarson DA, Bissell K, Billo NE. Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. Allergy 2007;62:230236.